Evidence map›Paper›PMID 41460588›Full record

ArticleBreast cancer research and treatment2025

Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study.

Mary U O Olomu, Casey Scherer, Emily Wood, Kasandra Escobar, Sacha Moufarrej, Rafaay Kamran, Shannon Muir, Fatima Muñoz, Mariana Stern, Scarlett Gomez and 10 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05916378 (Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05916378 completednot on this map

Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies

TypeobservationalSponsorStanford UniversityRan2023 to 2026Enrolled514ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mary U O OlomuDivision of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Casey SchererSchool of Medicine, Stanford, CA, USA.
Emily WoodDivision of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Kasandra EscobarDivision of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Sacha MoufarrejUniversity of California San Diego School of Medicine, San Diego, USA.
Rafaay KamranUniversity of California Los Angeles School of Medicine, Los Angeles, USA.
Shannon MuirStanford Cancer Institute, Stanford, USA.
Fatima MuñozSan Ysidro Health Center, San Diego, USA.
Mariana SternUniversity of Southern California Keck School of Medicine, Los Angeles, USA.
Scarlett GomezUniversity of California San Francisco School of Medicine, San Francisco, USA.
Douglas W BlayneyDivision of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Helen ChewUniversity of California Davis School of Medicine, Sacramento, USA.
Lisa M TealerBay Area Community Health Advisory Council, San Mateo, USA.
Amy AlanesWomen's Cancer Resource Center, Berkeley, USA.
Dolores MooreheadWomen's Cancer Resource Center, Berkeley, USA.
Mayte SanchezCancer Resource Centers of Mendocino County, Stanford, USA.
Keily Becerra SánchezCancer Resource Centers of Mendocino County, Stanford, USA.
Stacey TinianovAdvocates for Collaborative Education, Santa Cruz, USA.
Ysabel Duron *Latino Cancer Institute, San Jose, USA.
Manali I Patel *Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. manalip@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenomic testing informs treatment decisions for estrogen receptor-positive, progesterone receptor-positive, and HER2-negative early-stage breast cancer, yet uptake remains disproportionately low among racially and ethnically minoritized and low-income populations. Understanding the multilevel barriers driving these disparities is essential for equitable delivery of personalized cancer care. This study explores barriers to and potential solutions for equitable access to genomic testing, incorporating perspectives from patients, caregivers, clinicians, navigators, payers, and policymakers.

methodsWe conducted a qualitative study using community-based participatory research principles in partnership with five community-based organizations. Semi-structured interviews were completed with 32 participants: patients (n = 20), caregivers (n = 2), clinicians (n = 4), navigators (n = 2), payers (n = 2), and policymakers (n = 2). Transcripts were analyzed using constructivist grounded theory and interpretive description.

resultsThree major themes emerged: (1) Limited awareness and information across interested groups, including confusion between genomic and genetic testing, particularly among patients, caregivers, and some healthcare staff; (2) Modifiable challenges in accessing genomic testing, such as administrative complexity, insurance barriers, and financial toxicity; and (3) Racial, ethnic, and socioeconomic factors, including language barriers and lack of culturally appropriate materials, that impede equitable access to testing.

conclusionsEquitable delivery of genomic testing in breast cancer requires multilevel interventions targeting structural barriers, administrative complexity, and culturally tailored education. Addressing these barriers is likely to reduce disparities and further improve health equity in cancer care.

Indexed as

Breast NeoplasmsGenetic TestingHealth Services AccessibilityAdultAgedCommunity-Based Participatory ResearchFemaleGenomicsHealthcare DisparitiesHumansMiddle AgedQualitative ResearchBreast cancerCommunity-engaged researchGenomic testingHealth disparitiesHealth equity

Identifiers

PMID41460588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.